Please assess the completion status of the following clinical trial:

Trial Title: FMS European Long-Term Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patient who completed the 3-month F02207 GE 302 study~* patient with a diagnosis of fibromyalgia according to the 1990 ACR criteria at entry of F02207 GE 302 study~Exclusion Criteria:~* known hypersensitivity to milnacipran~* major depressive episode~* significant risk of suicide~* generalised anxiety disorder~* substance abuse~* clinically significant cardiac disease~* pulmonary dysfunction~* active liver disease~* renal impairment~* autoimmune disease~* current systemic infection~* epileptic~* active cancer~* severe sleep apnoea~* active peptic ulcer~* inflammatory bowel disease~* unstable endocrine disease~* (for men) prostatic enlargement or other genito-urinary disorders~* (for women) pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- Minalcipran 100 mg (Type: EXPERIMENTAL): None
- Minalcipran 150 mg (Type: EXPERIMENTAL): None
- Minalcipran 200 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).